Somewhat Favorable News Coverage Somewhat Unlikely to Affect BIOLASE (BIOL) Stock Price
Press coverage about BIOLASE (NASDAQ:BIOL) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. BIOLASE earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave news stories about the medical technology company an impact score of 46.732764582311 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Growing incidences of oral diseases to boost the growth of dental equipment market in future detailed in new research report (whatech.com)
- Lanman Appointed to Biolase Board (photonics.com)
- Biolase (BIOL) Commences Rights Offering (streetinsider.com)
- BIOLASE Announces Commencement of Rights Offering (finance.yahoo.com)
- ETFs with exposure to BIOLASE, Inc. : November 9, 2017 (finance.yahoo.com)
BIOLASE (NASDAQ BIOL) traded down $0.01 on Tuesday, reaching $0.57. The company’s stock had a trading volume of 60,500 shares, compared to its average volume of 121,833. BIOLASE has a one year low of $0.48 and a one year high of $1.90.
BIOLASE Company Profile
BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.
Receive News & Stock Ratings for BIOLASE Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE Inc and related stocks with our FREE daily email newsletter.